Jane Street Group LLC Has $47,000 Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Jane Street Group LLC lessened its stake in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) by 84.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 45,952 shares of the company’s stock after selling 244,307 shares during the period. Jane Street Group LLC owned about 0.06% of Protalix BioTherapeutics worth $47,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of PLX. Cubist Systematic Strategies LLC bought a new position in shares of Protalix BioTherapeutics during the second quarter worth approximately $37,000. GSA Capital Partners LLP raised its position in Protalix BioTherapeutics by 8.5% during the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock worth $444,000 after purchasing an additional 33,969 shares during the last quarter. AQR Capital Management LLC bought a new position in Protalix BioTherapeutics during the 2nd quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Protalix BioTherapeutics in the 2nd quarter worth about $80,000. Finally, Squarepoint Ops LLC raised its position in shares of Protalix BioTherapeutics by 673.3% in the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock worth $161,000 after acquiring an additional 119,949 shares in the last quarter. Institutional investors own 16.53% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Protalix BioTherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, December 12th.

Protalix BioTherapeutics Stock Performance

PLX stock opened at $2.17 on Thursday. The company has a market capitalization of $159.79 million, a P/E ratio of -16.69 and a beta of 0.71. Protalix BioTherapeutics, Inc. has a 52-week low of $0.82 and a 52-week high of $2.36. The business has a 50-day simple moving average of $1.76 and a two-hundred day simple moving average of $1.31.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.